Relevant bibliographies by topics / Ca 19-9 (antigene)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Ca 19-9 (antigene)'

Author: Grafiati
Published: 4 June 2021
Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ca 19-9 (antigene).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ca 19-9 (antigene)"

1

Göhring, U. J., F. Weber, A. Scharl, and A. Bolte. "Vorkommen der tumorassoziierten Antigene CA 50 und CA 19-9 in Endometriumkarzinomen." Archives of Gynecology and Obstetrics 254, no. 1-4 (1993): 993–95. http://dx.doi.org/10.1007/bf02266273.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Montz, R., H. Greten, J. F. Chatal, et al. "Immunszintigraphie und Radioimmuntherapie des transplantierten Pankreaskarzinoms." Nuklearmedizin 24, no. 05 (1985): 227–31. http://dx.doi.org/10.1055/s-0038-1624307.

Full text
Abstract:
ZusammenfassungEs wird über Untersuchungen zur Immunszintigraphie von 12 humanen Pankreaskarzinomen berichtet, die auf der Nacktmaus (Nu-Nu-Balb-C) etabliert werden konnten. Diese transplantierten Tumoren entsprachen von seiten der Histologie, des Gradings, der Immunhistochemie und der Sekretion der tumorassoziierten Antigene den humanen Karzinomen. Die Untersuchungen wurden mit 131J-markierten monoklonalen Antikörpern gegen tumorassoziierte Antigene (Ca 19-9, CEA und CA 125) durchge-führt, die zusammen in über 90% bei Patienten mit Pankreaskarzinomen zum Zeitpunkt der Primärdiagnostik im Serum nachweisbar sind. Die Ergebnisse zeigen, daß Pankreaskarzinome immunszintigraphisch mit die-sen markierten Antikörpern darstell-bar sind. Die Qualitat der Darstellung hängt u. a. von der Affinität der Anti-körper zum Tumor, der Tumorlokalisation und der Tumorgröße ab. Die ersten Ergebnisse zur Radioimmuntherapie des Pankreaskarzinoms mit 131J-anti-CA 19-9 zeigen, daß eine wirksame Strahlendosis im Tumor durch intravenöse Injektion nur bei ‘ hoher Antigenexpression im Tumor-gewebe möglich scheint. Nach intratumoraler Gabe ließ sich dagegen auch bei mäßiger Affinität eine thera-peutische Strahlendosis im Tumor mit geringer Ganzkörperbelastung erreichen. Dies ergab sich aus folgenden Untersuchungen: An insgesamt 8 Mäusen mit immunhistochemisch positiven (n = 2) und negativen (n = 1) Pankreaskarzinomen wurde die An-reicherung und die effektive Halb-wertszeit von 131J-anti-Ca 19-9 nach intratumoraler (100 μCi/mm3 Tumor) oder intravenöser (30 und 190 μCi/g Körpergewicht) Applikation gemessen.
APA, Harvard, Vancouver, ISO, and other styles
3

Pejcic, Ivica, Svetislav Vrbic, Sladjana Filipovic, et al. "Significance of serum tumor markers monitoring in carcinomas of unknown primary site." Vojnosanitetski pregled 67, no. 9 (2010): 723–31. http://dx.doi.org/10.2298/vsp1009723p.

Full text
Abstract:
Background/Aim. Unknown primary tumors represent a heterogeneous group of malignancies that are indicative of ominous prognosis. Cancer of unknown primary site (CUP) is defined as the lack of any detectable primary site after full evaluation, and accounts for approximately 3-5% of all newly diagnosed patients with malignancies. The aim of this report was to present the prognostic and predictive value of 8 serum tumor markers in this group of patients. Methods. The study involved 63 patients. On histological examination, all the patients were presented with metastatic tumors whose primary site (origin) could not be detected with noninvasive diagnostic techniques. Following the routine light microscopy, all histological findings were classified into one of the following three groups: plano-cellular carcinoma - 8 patients; adenocarcinoma - 33 patients; unclassifiable (undifferentiated) carcinoma - 22 patients. In all the cases we evaluated 8 serum tumor markers: alpha-fetoproteins (AFP), chronic gonadotrophin beta submit, human (beta-HCG), neuron specific enolase (NSE), marker of malignant ovarian tumors (CA 125), prostate-specific antigene (PSA), marker of malignant brest tumor (CA 15-3), marker of malignant pancreas tumor and gastrointestinal tumor (Ca 19-9), carcinoembryonic antigen (CEA) at the time of diagnosis. The patients on chemotherapy had the markers determined after the third and sixth chemocycle, i.e. at the time of illness progression observation, if present. The patients responding to chemotherapy with complete response (CR), partial response (PR) or stable disease (SD) had the markers determined after three-month periods until the time of relapse or progression. Chemotherapy was applied in 32 patients (20 females and 12 males), aged 29-70 years, who met the inclusion criteria. The following chemotherapy regimen was used: doxorubicin 50mg/m2 (day 1), cisplatin 60mg/m2 (day 1), and etoposide 120 mg/m2 (days 1-3). The period between two chemotherapy cycles was three weeks, and maximum five weeks in the case of prolonged hematological toxicity. Results. Most commonly elevated were NSE values (82.54%), while AFP values were least commonly elevated (11.11%). Average survival time was 17.89 months (95%CI 12.96; 22.83). The probability of 24 months' survival was 0.228. The group of 32 patients treated with chemotherapy had 12 (37.5%) fatal outcomes in the observed period (72 months). Average survival time was 26.6 months (95% CI 19.5; 33.7). Average tumor marker values before and after the chemotherapy were significantly lower for NSE and CA 125. Survival was significantly better in cases of NSE and CA 125 decrease of more than 20%. Conclusion. Increased values of serum tumor markers are very often in CUP. The tumors show nonspecific overexpression of tumor markers. The NSE and CA 125 levels show good correlation with response to the given chemotherapy. However, a routine evaluation of commonly used serum tumor markers has not been proven of any prognostic and predictive assistance.
APA, Harvard, Vancouver, ISO, and other styles
4

Lorenzi, M., C. Vindigni, C. Minacci, et al. "Histopathological and Prognostic Evaluation of Immunohistochemical Findings in Colorectal Cancer." International Journal of Biological Markers 12, no. 2 (1997): 68–74. http://dx.doi.org/10.1177/172460089701200205.

Full text
Abstract:
Many immunohistochemical studies have investigated the relationship between immunohistochemical characteristics and histopathological findings in colorectal tumors. One of the most extensively studied markers has been tissue CEA, although the prognostic significance of this and other antigens is still uncertain. The authors report results relative to three tumoral antigens (carcinoembryonic antigen, CEA; tissue polypeptide antigen, TPA, and carbohydrate antigen 19–9, CA 19–9) determined by immunohistochemical methods in tissue samples of 52 colorectal carcinomas. The relationship between the immunohistochemical characteristics of the neoplasms and the clinicopathologic parameters, as well as their influence on the prognosis of the patients, were examined. Positive CEA reaction has a significant relationship with grade of differentiation of the tumor while diffuse cellular expression of this antigen often indicates neoplasms extending beyond the intestinal wall and invading the lymph vessels. The number of tissue antigens expressed is significantly related to the extent of tumor spread through the intestinal wall. A greater incidence of recurrence and shorter disease-free interval and survival were observed in neoplasms that expressed tissue TPA antigen or more than one tissue antigens. In the present study the latter parameter has demonstrated to have independent prognostic significance for the disease-free interval. Immunohistochemical evaluation of antigens in colorectal carcinoma tissue shows a possible independent prognostic value of the antigenic heterogeneity of tumors, which could be related to their different biological behavior.
APA, Harvard, Vancouver, ISO, and other styles
5

Nanayakkara, S., S. Ali, and K. Gilmour. "Increased serum carcinomic antigen 19-9(CA 19-9) in a dermoid cyst." Journal of Obstetrics and Gynaecology 27, no. 1 (2007): 96–97. http://dx.doi.org/10.1080/01443610601076259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Holtzman, Robert N. N., A. Douglas Heymann, Fausto Bordone, Gianfilippo Marinoni, Paolo Barillari, and Samuel J. Wahl. "Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Immunostaining in Benign Multicystic Mesothelioma of the Peritoneum." Archives of Pathology & Laboratory Medicine 125, no. 7 (2001): 944–47. http://dx.doi.org/10.5858/2001-125-0944-caacai.

Full text
Abstract:
Abstract A 58-year-old Italian man was incidentally discovered to have an elevated carbohydrate antigen 19-9 (CA-19-9) level of 132 U/mL on routine blood testing. Multisystem imaging studies revealed multiple benign-appearing cysts of the liver and single cysts in the pancreas and kidney parenchyma. Throughout 14 months, fluctuations were observed in the elevated serum CA-19-9 levels from 99 to 450 U/mL. Serum carcinoembryonic antigen (CEA) and other tumor markers were normal. Laparoscopy disclosed multiple cystic lesions on the surface of the liver, on the serosal surface of the ileum, and in the mesentery. Electron microscopy characterized the cells as mesothelial. The pathologic diagnosis was benign multicystic mesothelioma of the peritoneum (BMMP). Aspirated fluid from the liver cyst revealed CA-19-9 levels at 28 500 U/mL, strongly linking the elevated serum CA-19-9 levels with mesothelial cyst secretion. Immunostaining was positive for CA-19-9, CEA, and cancer antigen 125 (CA-125). We believe this is the first documented instance of CA-19-9 and CEA secretion in BMMP.
APA, Harvard, Vancouver, ISO, and other styles
7

Dyckhoff, Gerhard, Rolf Warta, Achim Gonnermann, Peter Karl Plinkert, Christa Flechtenmacher, and Martin Volkmann. "Carbohydrate Antigen 19-9 in Saliva." Otolaryngology–Head and Neck Surgery 145, no. 5 (2011): 772–77. http://dx.doi.org/10.1177/0194599811414512.

Full text
Abstract:
Objective. Facial nerve preservation and oncological safety are crucial in surgery of parotid tumors. An unexpected histopathologic diagnosis of a malignant parotid tumor, however, may unfavorably require a second, more radical surgery. The aim of this study was to find out whether the assessment of serological tumor markers in parotid saliva might have some diagnostic significance in the preoperative differentiation between benign and malignant parotid lesions. Study Design, Setting, Patients, and Methods. In a prospective pilot study performed at a university medical center in 28 patients with a unilateral parotid tumor, 7 serological tumor markers established in the clinical routine were quantitatively assessed in parotid saliva collected simultaneously on both sides after stimulation. The results were correlated with the histopathological diagnosis. Results. Of the 4 investigated tumors that were malignant neoplasms, 3 had a sufficient quantity of saliva available for tumor marker measurements. Carbohydrate antigen 19-9 (CA 19-9) consistently revealed high levels compared with the unaffected side in all malignant tumors, thus allowing malignant tumors to be differentiated from benign lesions. Conclusion. The results of this pilot study are encouraging, showing that preoperative tumor marker investigation in saliva from parotid glands is feasible and merits further investigation. CA 19-9 might be a valuable new diagnostic tool in the preoperative differentiation between malignant and benign parotid tumors and should be investigated in a larger number of patients.
APA, Harvard, Vancouver, ISO, and other styles
8

Baynes, Cayla, та Jeong-Yeol Yoon. "μPAD Fluorescence Scattering Immunoagglutination Assay for Cancer Biomarkers from Blood and Serum". SLAS TECHNOLOGY: Translating Life Sciences Innovation 23, № 1 (2017): 30–43. http://dx.doi.org/10.1177/2472630317731891.

Full text
Abstract:
A microfluidic paper analytical device (μPAD) was created for the sensitive quantification of cancer antigens, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9), from human whole blood and serum, toward diagnosis and prognosis of colorectal cancer. Anti-CEA and anti–CA 19-9 antibodies were covalently linked to submicron, fluorescent polystyrene particles, loaded, and then dried in the center of the μPAD channel. CEA- or CA 19-9–spiked blood or serum samples were loaded to the inlet of μPAD, and subsequent immunoagglutination changed the fluorescent scatter signals upon ultraviolet (UV) excitation. The total assay time was about 1 min. Detection limits were 1 pg/mL for CEA and 0.1 U/mL for CA 19-9 from both 10% diluted blood and undiluted serum. The use of UV excitation and subsequent fluorescence scattering enabled much higher double-normalized intensities (up to 1.28–3.51, compared with 1.067 with the elastic Mie scatter detection), successful detection in the presence of blood or serum, and distinct multiplex assays with minimum cross-reaction of antibodies. The results with undiluted serum showed the larger dynamic range and smaller standard errors, which can be attributed to the presence of serum proteins, functioning as a stabilizer or a passivating protein for the particles within paper fibers.
APA, Harvard, Vancouver, ISO, and other styles
9

Shahangian, S., H. A. Fritsche, J. I. Hughes, and F. B. Gelder. "Pancreatic oncofetal antigen and carbohydrate antigen 19-9 in sera of patients with cancer of the pancreas." Clinical Chemistry 35, no. 3 (1989): 405–8. http://dx.doi.org/10.1093/clinchem/35.3.405.

Full text
Abstract:
Abstract Pancreatic oncofetal antigen (POA) and carbohydrate antigen 19-9 (CA 19-9) were measured in the sera of 23 patients with cancer of the pancreas to determine the true positive rates of these cancer markers. In one group of unselected pancreatic cancer patients (n = 9), both tests showed above-normal results in three patients and both gave values that were within reference limits in three other patients. Two of the three remaining patients had increased CA 19-9 but normal POA values, and one patient had increased POA but normal CA 19-9 concentrations in serum. In another group of 14 pancreatic cancer patients, selected on the basis of increased concentrations of POA in serum, the CA 19-9 values were increased in eight. In four patients who had progressive disease, the concentrations of both markers increased with time in one patient, only POA in one, and only CA 19-9 concentration in another. (The fourth patient had increased but stable concentrations of POA and CA 19-9 in serum.) These data suggest that serum POA and CA 19-9 measurements should be used in combination in the evaluation of patients with cancer of the pancreas.
APA, Harvard, Vancouver, ISO, and other styles
10

Atkins, Carl D. "CA 19-9 and Lewis Antigens in Pancreatic Cancer." Journal of Clinical Oncology 27, no. 15 (2009): 2572–73. http://dx.doi.org/10.1200/jco.2009.21.8198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Ca 19-9 (antigene)"

1

OTTO, JOSIANE. "Elevation du ca 19-9 dans les fibroses pulmonaires idiopathiques." Nice, 1992. http://www.theses.fr/1992NICE6575.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

PINGANNAUD, MARIE-PIERRE. "Apport du dosage de l'ace et du ca 19-9 dans le diagnostic des collections kystiques pancreatiques." Aix-Marseille 2, 1992. http://www.theses.fr/1992AIX20812.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hartmann, Marie-Thérèse. "Interet du scc ta-4 dans le cancer epidermoide de l'oesophage par rapport a l'ace - ca 19-9 - ca 125." Nice, 1991. http://www.theses.fr/1991NICE6508.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

BELJIO, KATIA. "Elevation du ca 19. 9 au cours des rhumatismes inflammatoires dysimmunitaires : a propos de six observations." Toulouse 3, 1992. http://www.theses.fr/1992TOU31041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

BILDSTEIN, LAURE. "Evaluation quantitative des mucines conjonctivales par dosage du ca 19-9 sur empreintes." Dijon, 1994. http://www.theses.fr/1994DIJOM061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Le, Thi Nhu Van. "Intérêt de l'ACE et du CA 19. 9 pour le suivi des malades sous chimiothérapie pour un cancer digestif." Montpellier 1, 1992. http://www.theses.fr/1992MON11229.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Colombie, Alain. "Valeurs et limites de dosage de l'antigène Ca 19-9 dans le diagnostic et la surveillance des cancers du pancréas." Montpellier 1, 1989. http://www.theses.fr/1989MON11012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

DOREY, LAMARQUE MARIE-PIERRE. "L'elevation serique du ca 19-9 en dehors des neoplasies : etude sur 183 dosages realises dans un service de medecine interne." Saint-Etienne, 1993. http://www.theses.fr/1993STET6229.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tripp-Friedrich, Kerstin. "Diagnostik, Therapie und Prognose seltener Pankreastumoren." Ulm : Universität Ulm, Medizinische Fakultät, 2002. http://www.bsz-bw.de/cgi-bin/xvms.cgi?SWB10028614.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lopes, Roberto Iglesias. "Avaliação dos valores séricos e urinários de CA 19-9 e TGFbeta1 na obstrução parcial e completa de ureteres em ratos." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5153/tde-29042014-101952/.

Full text
Abstract:
Introdução: A alteração dos níveis normais de marcadores séricos e urinários ocorre na presença de dano renal associado à uropatia obstrutiva. Valores séricos e e urinários de TGF beta1 e CA 19-9 ainda não foram avaliados em modelo experimental de uropatia obstrutiva. Material e Métodos: Ratos foram divididos em sete grupos: referência, sham operation, nefrectomia unilateral, ligadura completa de ureter unilateral, obstrução parcial de ureter unilateral, obstrução parcial de ambos ureteres, nefrectomia unilateral associada à obstrução parcial do ureter contralateral. Morfometria renal e ureteral, concentrações séricas e urinárias de TGF beta1 e CA 19-9 e expressão tecidual renal de CA 19-9 foram analisadas. A correlação destes marcadores com os grupos submetidos a obstrução completa, obstrução parcial ou sem obstrução foi realizada. Resultados: Achados anatomopatológicos correlacionaram-se positivamente à intensidade da obstrução ureteral e negativamente aos níveis urinários de CA 19-9. Subexpressão acentuada do CA 19-9 foi observada em unidades renais com obstrução completa. Não foram encontradas diferenças estatisticamente significativas para os marcadores TGF beta1 urinário, TGF beta1 sérico e para o CA 19-9 sérico Conclusões: O CA 19-9 urinário correlacionou-se negativamente com o grau de obstrução ureteral. A análise imuno-histoquímica demonstrou a expressão do CA 19-9 no citoplasma das células epiteliais tubulares, sugerindo produção renal do marcador. O TGF beta1 sérico e urinário não apresentaram modificações de acordo com o grau de severidade e tempo de obstrução, o que pode estar relacionado a remodelamento renal menos intenso em resposta à uropatia obstrutiva nestes ratos
Introduction: Abnormal levels of serum and urinary markers occur in the presence of renal damage associated to obstructive uropathy. Urinary and serum TGFbeta1 and CA 19- 9 have not yet been evaluated in an experimental model of obstructive uropathy. Material and Methods: Rats were divided into seven groups: reference, sham operation, unilateral nephrectomy, complete unilateral ureteral obstruction, partial unilateral ureteral obstruction, partial bilateral ureteral obstruction, and unilateral nephrectomy with contralateral partial ureteral obstruction. Kidney and ureter morphometry, TGFbeta1 and CA 19-9 serum and urinary concentrations and CA 19-9 renal tissue expression were analysed. Correlation of these markers to complete, partial obstruction or unobstructed groups was performed. Results: Pathological findings correlated positively with the degree of ureteral obstruction, but negatively with urinary CA 19-9 levels. Marked underexpression of CA 19-9 was observed in kidneys with complete ureteral obstruction. No statistically significant differences were found for urinary and serum TGFbeta1 and also for serum CA 19-9. Conclusions: Urinary CA 19-9 correlated negatively with ureteral obstruction grade. Immunohistochemistry depicted CA 19-9 expression on epithelial tubular cells cytoplasm, suggesting renal origin. Serum and urinary TGFbeta1 did not show alterations in response to severity and length of urinary obstruction, which might be associated with less intense renal remodeling
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Ca 19-9 (antigene)"

1

Göhring, U. G., F. Weber, A. Scharl, and A. Bolte. "Vorkommen der tumorassoziierten Antigene CA 50 und CA 19-9 in Endometriumkarzinomen." In Gynäkologie und Geburtshilfe 1992. Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-77857-5_382.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ward, Tony Milford. "Carbohydrate Antigen CA 19-9." In Proteins and Tumour Markers May 1995. Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0681-8_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lamerz, Rolf. "CA 19–9, GICA (Gastrointestinal Cancer Antigen)." In Serological Cancer Markers. Humana Press, 1992. http://dx.doi.org/10.1007/978-1-4612-0401-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Maehara, Masanori, Akio Yamaguchi, Takanori Goi, Kazuo Hirose, Yoshiaki Isobe, and Gizo Nakagawara. "The Relationship Between Metastatic Potential and the Expression of Sialyl Lewis A (CA 19–9) and Sialyl Lewis X Antigens in Colorectal Cancer." In Recent Advances in Management of Digestive Cancers. Springer Japan, 1993. http://dx.doi.org/10.1007/978-4-431-68252-3_146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

ARENDS, J. W., T. WIGGERS, B. SCHUTTE, et al. "The Value of Centocor CA 19-9 Tm OR Gastrointestinal Cancer Associated Antigen (GICA) in the Diagnosis and Prognosis of Colorectal Cancer." In Protides of the Biological Fluids. Elsevier, 1985. http://dx.doi.org/10.1016/b978-0-08-031739-7.50156-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ca 19-9 (antigene)"

1

Thomas, Dhanya S., Ajit Sebastian, Vinotha Thomas, Anitha Thomas, Rachel Chandy, and Abraham Peedicayil. "Role of cancer antigen 19-9 in complex ovarian tumors." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685315.

Full text
Abstract:
Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA 19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, were included in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors. Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were nonmucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.
APA, Harvard, Vancouver, ISO, and other styles
2

Thomas, Dhanya S., Ajit Sebastian, Vinotha Thomas, Anitha Thomas, Rachel Chandy, and Abraham Peedicayil. "Role of CA 19-9 in complex ovarian tumors." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685299.

Full text
Abstract:
Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, wereincluded in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 - benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors.Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were non mucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.
APA, Harvard, Vancouver, ISO, and other styles
3

Pandey, Divya, Neha Pruthi, and Sudha Salhan. "Unusually high serum Ca 19-9 in a benign ovarian tumor." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685327.

Full text
Abstract:
Introduction: Ovarian tumors have a varied spectrum of presentation. Tumors which look malignant clinico-biochemically can ultimately turn out to be benign. Tumor markers help in diagnosing various malignancies. Carbohydrate antigen 19-9 is one such marker seen to be elevated in some ovarian tumors. Case: A 55 year old, lean and thin postmenopausal female presented to Gynae OPD with abdominal mass, anorexia and weight loss developing over last 6 months. During workup, she was found to have unusually high Ca 19-9 along with MRI findings suggestive of ovarian tumor. Staging laparotomy followed by total abdominal hysterectomy with bilateral salpingoophorectomy was performed. Per operative findings were suggestive of benign nature of ovarian tumor of size 18× 20 cm. Patient was kept under follow up. Histopathology report showed benign mucinous cystadenoma. The serum levels of Ca19-9 returned to normal 8 weeks following surgery. This case report shows a rare and significant elevation of Ca19-9 levels with benign mucinous cystadenoma of the ovary, thus showing that women with unusually elevated tumor markers and even symptoms suggesting malignancy may actually harbour a benign disease. Conclusion: Unusually high Ca 19-9 may be associated with benign mucinous cystadenoma but thorough workup to rule out malignancy is a must in every case.
APA, Harvard, Vancouver, ISO, and other styles
4

Yue, Tingting, Mary C. Hurley, Randel E. Brand, Philip C. Andrews, and Brian B. Haab. "Abstract 5567: Pancreatic disease-specific carriers of the CA 19-9 antigen identified by antibody microarrays and mass spectrometry." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-5567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yue, Tingting, Kevin Maupin, Katie Partyka, et al. "Abstract 2216: Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-2216.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography